We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus (MOMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01821508
Recruitment Status : Completed
First Posted : April 1, 2013
Last Update Posted : May 28, 2021
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Ricardo Vitor Cohen, MD, Hospital Alemão Oswaldo Cruz

Brief Summary:

This is a prospective, open, randomized study involving 100 patients with microvascular complications of type 2 diabetes mellitus and obesity, who will undergo gastric bypass (Roux-en-Y gastric bypass ARM A) or receive best medical treatment (ARM B, control arm).

The aim of this study is to evaluate the effects of Roux-en-Y gastric bypass in the control of diabetic nephropathy in diabetic patients with BMI between 30 and 35 kg/m2.

The medical community is confronted with many different studies using various methodologies to investigate the best pharmacological treatment for type 2 diabetes mellitus. The treatment algorithm offers several different options according to the stage of the disease (which is different in each study). In addition, new drugs are being developed over the years, but are not always a guarantee of effective type 2 diabetes mellitus control [MENDES, 2010]. Furthermore, these drugs do not prevent the development of this disease, consequently increasing the risks of microvascular and macrovascular complications.

Conversely, there is considerable evidence that surgery can be an adequate tool to promote type 2 diabetes mellitus remission in patients who are unresponsive to clinical treatment. Gastric bypass surgery is one of the most popular bariatric surgeries in the world, but its effects on microvascular and macrovascular complications of type 2 diabetes mellitus have not been established. Specialists suggest that the rapid and uncontrollable decrease in blood glucose adds to the concern that the surgery may paradoxically cause exacerbation of microvascular complications [LEOW, 2005], whereas gradual improvement in blood glucose before gastric bypass surgery may prevent this paradoxical worsening, leading to an interruption of this process, or even retinopathy, nephropathy, and neuropathy remission.

However, there are no studies comparing the results of these two types of treatment (clinical vs. surgical) in a similar population and assessing the development of microvascular complications of type 2 diabetes mellitus. Therefore, in order to clarify such doubts, it is necessary and extremely desirable to conduct a randomized controlled trial comparing gastric bypass with the best and most modern clinical treatment. Its findings could have a direct impact on hundreds of millions of diabetics by allowing the inclusion of surgical treatment as a safe and feasible therapeutic option for a significant portion of these patients.

Condition or disease Intervention/treatment Phase
Complications of Diabetes Mellitus Other: Clinical Treatment Procedure: Roux-En-Y gastric bypass surgery Not Applicable

Detailed Description:
Intervention of Roux-En-Y gastric bypass surgery versus best medical treatment in control or reduces microvascular complications such as retinopathy, microalbuminuria and neuropathic.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open,Randomized, Unicentre Study Comparing Roux-en-Y Gastric Bypass With the Best Clinical Treatment Regarding Improvement of Microvascular Complications of Type 2 Diabetes Mellitus in Obese Patients.
Actual Study Start Date : April 18, 2013
Actual Primary Completion Date : April 29, 2021
Actual Study Completion Date : April 29, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Clinical treatment
Best and most modern clinical treatment of type 2 diabetes mellitus.
Other: Clinical Treatment
metabolic surgery for diabetes and weight control
Other Name: lifestyle changes for obesity

Active Comparator: Roux-En-Y gastric bypass surgery
A "metabolic" surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009].
Procedure: Roux-En-Y gastric bypass surgery
laparoscopic surgical procedure with Endoscopic Surgical Stapler

Primary Outcome Measures :
  1. The primary endpoint will be the proportion of patients that present normalization of the albumin/creatinine ratio in isolated urine samples (normal value considered as an albumin/creatinine ratio of less than 30 μg/mg ). [ Time Frame: 12, 24 and 60 months ]
    Number of participants achieving remission Titrating the relation of urinary albumin/creatinine

Secondary Outcome Measures :
  1. Changes in diabetic retinopathy [ Time Frame: 12, 24 and 60 months ]
    Number of patients achieving resolution or reduction in the degree of retinopathy and/or macular oedema (severity scale)

  2. Changes in diabetic peripheral neuropathy [ Time Frame: 12, 24 and 60 months ]
    Number of patients with new or worsening of neuropathy

  3. Use of pharmacological therapy for type 2 diabetes mellitus [ Time Frame: 12, 24 and 60 months ]
    Number of medications necessary for targeting euglycaemia

  4. Glycemic control [ Time Frame: 12, 24 and 60 months ]
    Number of patients achieving fasting glucose level < 100 and HbA1c < 6.5%

  5. Blood pressure control [ Time Frame: 12, 24 and 60 months ]
    Number of patients achieving systolic blood pressure <130 mm Hg and diastolic <80 mm Hg

  6. Lipids control [ Time Frame: 12, 24 and 60 months ]
    Number of patients with LDL<100 or <70 mg/dL in patients with previous cardiovascular events; HDL>50 mg/dL and triglycerides <150 mg/dL

  7. Quality of life (SF-36) [ Time Frame: 12, 24 and 60 months ]
    SF-36 questionnaire

  8. Changes in hepatic fibrosis [ Time Frame: 12, 24 and 60 months ]
    Reduction of hepatic elastographic resistance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female adult patients with microalbuminuria (more than 30 mg and less than 300 mg or more of urinary albumin per 24 hours), with or without other microvascular complications of type 2 diabetes mellitus, receiving pharmacological treatment for the disease, which may or may not include the use of insulin.
  • Age between 18-65 years
  • BMI between 30 and 35 Kg/m2
  • 15-year or less after type 2 diabetes mellitus diagnosis
  • Negative anti-glutamic acid decarboxylase
  • Fasting C-peptide higher than 1 ng/ml, increasing in the postprandial period (two hours after mixed meal, ENSURE plus approximately 500 Kcal)

Exclusion Criteria:

  • Patient's refusal to participate
  • Autoimmune diabetes mellitus
  • Previous abdominal surgeries that may make surgery more difficult, increasing the surgical risk
  • Previous malabsorptive and restrictive surgeries
  • Pregnant women and nursing mothers
  • Recent history of neoplasia (< 5 years), except for non-melanoma skin neoplasms
  • History of liver disease - liver cirrhosis -, active chronic hepatitis, active hepatitis B and hepatitis C
  • Malabsorptive syndromes and inflammatory bowel disease
  • Cardiovascular event (acute myocardial infarction, acute coronary syndrome, angioplasty, or bypass in the last 6 months)
  • Angina
  • Pulmonary embolism or severe thrombophlebitis in the last 2 years
  • Positive HIV serum testing
  • Psychiatric disorders, including dementia, active psychosis, severe depression, history of suicide attempts, use of illicit drugs, and excessive alcohol consumption in the last 12 months
  • Uncontrolled coagulopathy
  • Patients with severe retinopathy, nephropathy, and neuropathy (defined as high risk/advanced proliferative retinopathy or amaurosis; stage 5 of chronic kidney disease defined by glomerular filtration rate, patients who need dialysis or renal transplantation; stage 3 of peripheral neuropathy)
  • Patients who participated in other clinical trials in the past 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01821508

Layout table for location information
Hospital Alemão Oswaldo Cruz
São Paulo, Brazil, 01323-020
Sponsors and Collaborators
Hospital Alemão Oswaldo Cruz
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Layout table for investigator information
Principal Investigator: Ricardo V Cohen, MD. PhD Hospital Alemão Oswaldo Cruz
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ricardo Vitor Cohen, MD, MD, PhD, Hospital Alemão Oswaldo Cruz
ClinicalTrials.gov Identifier: NCT01821508    
Other Study ID Numbers: MOMS
First Posted: April 1, 2013    Key Record Dates
Last Update Posted: May 28, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Ricardo Vitor Cohen, MD, Hospital Alemão Oswaldo Cruz:
Gastroplasty, Diabetes Mellitus Type II, Obesity
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Complications
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases